Designed ankyrin repeat proteins: A novel tool for testing epidermal growth factor receptor 2 expression in breast cancer

Modern Pathology

Volumn 23, Issue 9, 2010, Pages 1289-1297

  Theurillat, Jean Philippe ^a   Dreier, Birgit ^b   Nagy Davidescu, Gabriela ^b   Seifert, Burkhardt ^b   Behnke, Silvia ^a   Zürrer Härdi, Ursina ^a   Ingold, Fabienne ^a   Plückthun, Andreas ^b   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PARAFFIN;

ARTICLE; BINDING AFFINITY; BIOTINYLATION; BREAST CANCER; CANCER TISSUE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SCORING SYSTEM; TISSUE MICROARRAY; TISSUE SECTION;

ANKYRIN REPEAT; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PROTEIN BINDING; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 77956292486     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.103     Document Type: Article

References (31)

1. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: 1659-1672.
4. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809-820.
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
6. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-1411.
7. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5:63-69.
8. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1972-1977.
9. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854.
10. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006; 24:3032-3038.
11. Dal Lago L, Durbecq V, Desmedt C, et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 2006;5:2572-2579.
12. Vera-Roman JM, Rubio-Martinez LA. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med 2004;128:627-633.
13. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-857.
14. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27:1323-1333.
15. Sarkar CA, Dodevski I, Kenig M, et al. Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity. Proc Natl Acad Sci USA 2008;105:14808-14813.
16. Steiner D, Forrer P, Plückthun A. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display. J Mol Biol 2008;382:1211-1227.
17. Zahnd C, Amstutz P, Plückthun A. Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat Methods 2007;4:269-279.
18. Binz HK, Stumpp MT, Forrer P, et al. Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 2003;332:489-503.
19. Forrer P, Binz HK, Stumpp MT, et al. Consensus design of repeat proteins. Chembiochem 2004;5:183-189.
20. Binz HK, Amstutz P, Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005;23:1257-1268.
21. Binz HK, Kohl A, Plückthun A, et al. Crystal structure of a consensus-designed ankyrin repeat protein: implications for stability. Proteins 2006;65:280-284.
22. Interlandi G, Wetzel SK, Settanni G, et al. Characterization and further stabilization of designed ankyrin repeat proteins by combining molecular dynamics simulations and experiments. J Mol Biol 2008;375: 837-854.
23. Merz T, Wetzel SK, Firbank S, et al. Stabilizing ionic interactions in a full-consensus ankyrin repeat protein. J Mol Biol 2008;376:232-240.
24. Amstutz P, Koch H, Binz HK, et al. Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. Protein Eng Des Sel 2006; 19:219-229.
25. Kawe M, Forrer P, Amstutz P, et al. Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening. J Biol Chem 2006;281:40252-40263.
26. Zahnd C, Pecorari F, Straumann N, et al. Selection and characterization of Her2 binding-designed ankyrin repeat proteins. J Biol Chem 2006;281: 35167-35175.
27. Zahnd C, Wyler E, Schwenk JM, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 2007;369:1015-1028.
28. Theurillat JP, Zürrer-Hardi U, Varga Z, et al. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother 2007; 56:1723-1731.
29. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010;70:1595-1605.
30. Gullberg M, Jarvius J, Olsson C, et al. Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol 2002;20:473-477.
31. Söderberg O, Leuchowius KJ, Gullberg M, et al. Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 2008;45:227-232.